Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study

Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dose-dependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL). Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ENT updates 2016-12, Vol.6 (3), p.105-109
Hauptverfasser: Eskiizmir, Görkem, Çalıbaşı, Gizem, Uysal, Tuğba, Ellidokuz, Hülya, Baskın, Yasemin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 109
container_issue 3
container_start_page 105
container_title ENT updates
container_volume 6
creator Eskiizmir, Görkem
Çalıbaşı, Gizem
Uysal, Tuğba
Ellidokuz, Hülya
Baskın, Yasemin
description Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dose-dependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL). Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously monitored using the xCELLigence RTCA SP instrument. Thereafter, they were divided into seven groups as: (i) negative control: medium+OCSCCCL, (ii) positive control: medium+OCSCCCL+cisplatin 10 µM/ml, (iii) medium+OCSCCCL+cetuximab 25 µg/ml, (iv) medium+OCSCCCL+cetuximab 50 µg/ml, (v) medium+OCSCCCL+ cetuximab 100 µg/ml, (vi) medium+OCSCCCL+cetuximab 200 µg/ml, (vii) medium+OCSCCCL+cetuximab 400 µg/ml. The cell index and viability were statistically analyzed and compared between groups. Results: The distribution of cell index (mean value) and percentage of viability in groups were as follows: (i) 2.66 (100%), (ii) 0.17 (6.08%), (iii) 2.28 (85.71%), (iv) 2.31 (86.84%), (v) 1.92 (72.18%), (vi) 1.79 (67.29%), (vii) 0.28 (10.53%). The change trend in drug concentration was statistically different in all study groups to which cetuximab was administered (Pillai's trace; p
doi_str_mv 10.2399/jmu.2016003005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2399_jmu_2016003005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1908931744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c192t-a5168c22d9b3cbc1586eaa421edbbefd7699e891ec02fd1a78209ceb7fdcd1953</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMoOIyzdR1w3TGPtul1J4MvGHCj65Amt9ihk9QkFeff22EGXJ0L5-Nc-Ai55WwtJMD9bj-tBeM1Y5Kx6oIsBC-hqEtoLs-34gyuySqlvmVlqWQFql4Qt8E8_fZ701IzBI_0yyRqqAsJC4cjeoc-U-Nzn6d9iBS7Dm2mvachmoFa89PnwxzeYqQWhyE9zPSxn4sYaMqTO9yQq84MCVfnXJLP56ePzWuxfX952zxuC8tB5MJUvG6sEA5aaVvLq6ZGY0rB0bUtdk7VANgAR8tE57hRjWBgsVWds45DJZfk7rQ7xvA9Ycp6F6bo55eaA2tAclWWM7U-UTaGlCJ2eoyzgHjQnOmjTD3L1P8y5R9YUmkc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1908931744</pqid></control><display><type>article</type><title>Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Eskiizmir, Görkem ; Çalıbaşı, Gizem ; Uysal, Tuğba ; Ellidokuz, Hülya ; Baskın, Yasemin</creator><creatorcontrib>Eskiizmir, Görkem ; Çalıbaşı, Gizem ; Uysal, Tuğba ; Ellidokuz, Hülya ; Baskın, Yasemin</creatorcontrib><description>Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dose-dependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL). Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously monitored using the xCELLigence RTCA SP instrument. Thereafter, they were divided into seven groups as: (i) negative control: medium+OCSCCCL, (ii) positive control: medium+OCSCCCL+cisplatin 10 µM/ml, (iii) medium+OCSCCCL+cetuximab 25 µg/ml, (iv) medium+OCSCCCL+cetuximab 50 µg/ml, (v) medium+OCSCCCL+ cetuximab 100 µg/ml, (vi) medium+OCSCCCL+cetuximab 200 µg/ml, (vii) medium+OCSCCCL+cetuximab 400 µg/ml. The cell index and viability were statistically analyzed and compared between groups. Results: The distribution of cell index (mean value) and percentage of viability in groups were as follows: (i) 2.66 (100%), (ii) 0.17 (6.08%), (iii) 2.28 (85.71%), (iv) 2.31 (86.84%), (v) 1.92 (72.18%), (vi) 1.79 (67.29%), (vii) 0.28 (10.53%). The change trend in drug concentration was statistically different in all study groups to which cetuximab was administered (Pillai's trace; p&lt;0.0001). The antitumor effect of cetuximab was initially detected at a dose of 100 µg/mL, when compared with negative control (p=0.01). However, a dose of 400 µg/mL was required in order to have a statistically similar antitumor effect of cisplatin at a dose of 10 µM. Conclusion: Cetuximab alone is a potentially effective chemotherapeutic agent and has a concentration-dependent growth inhibitory effect in OCSCCCL. The antitumor activity of cetuximab was initially detected at a dose of 100 µg/mL. However, significant antitumor effect was determined at a dose of 400 µg/mL.</description><identifier>ISSN: 2149-7109</identifier><identifier>EISSN: 2149-6498</identifier><identifier>DOI: 10.2399/jmu.2016003005</identifier><language>eng</language><publisher>Istanbul: Continuous Education and Scientific Research Association (CESRA)</publisher><subject>Immunotherapy ; Monoclonal antibodies ; Oral cancer ; Targeted cancer therapy</subject><ispartof>ENT updates, 2016-12, Vol.6 (3), p.105-109</ispartof><rights>Copyright Continuous Education and Scientific Research Association (CESRA) Dec 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Eskiizmir, Görkem</creatorcontrib><creatorcontrib>Çalıbaşı, Gizem</creatorcontrib><creatorcontrib>Uysal, Tuğba</creatorcontrib><creatorcontrib>Ellidokuz, Hülya</creatorcontrib><creatorcontrib>Baskın, Yasemin</creatorcontrib><title>Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study</title><title>ENT updates</title><description>Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dose-dependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL). Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously monitored using the xCELLigence RTCA SP instrument. Thereafter, they were divided into seven groups as: (i) negative control: medium+OCSCCCL, (ii) positive control: medium+OCSCCCL+cisplatin 10 µM/ml, (iii) medium+OCSCCCL+cetuximab 25 µg/ml, (iv) medium+OCSCCCL+cetuximab 50 µg/ml, (v) medium+OCSCCCL+ cetuximab 100 µg/ml, (vi) medium+OCSCCCL+cetuximab 200 µg/ml, (vii) medium+OCSCCCL+cetuximab 400 µg/ml. The cell index and viability were statistically analyzed and compared between groups. Results: The distribution of cell index (mean value) and percentage of viability in groups were as follows: (i) 2.66 (100%), (ii) 0.17 (6.08%), (iii) 2.28 (85.71%), (iv) 2.31 (86.84%), (v) 1.92 (72.18%), (vi) 1.79 (67.29%), (vii) 0.28 (10.53%). The change trend in drug concentration was statistically different in all study groups to which cetuximab was administered (Pillai's trace; p&lt;0.0001). The antitumor effect of cetuximab was initially detected at a dose of 100 µg/mL, when compared with negative control (p=0.01). However, a dose of 400 µg/mL was required in order to have a statistically similar antitumor effect of cisplatin at a dose of 10 µM. Conclusion: Cetuximab alone is a potentially effective chemotherapeutic agent and has a concentration-dependent growth inhibitory effect in OCSCCCL. The antitumor activity of cetuximab was initially detected at a dose of 100 µg/mL. However, significant antitumor effect was determined at a dose of 400 µg/mL.</description><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Oral cancer</subject><subject>Targeted cancer therapy</subject><issn>2149-7109</issn><issn>2149-6498</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkEtLxDAUhYMoOIyzdR1w3TGPtul1J4MvGHCj65Amt9ihk9QkFeff22EGXJ0L5-Nc-Ai55WwtJMD9bj-tBeM1Y5Kx6oIsBC-hqEtoLs-34gyuySqlvmVlqWQFql4Qt8E8_fZ701IzBI_0yyRqqAsJC4cjeoc-U-Nzn6d9iBS7Dm2mvachmoFa89PnwxzeYqQWhyE9zPSxn4sYaMqTO9yQq84MCVfnXJLP56ePzWuxfX952zxuC8tB5MJUvG6sEA5aaVvLq6ZGY0rB0bUtdk7VANgAR8tE57hRjWBgsVWds45DJZfk7rQ7xvA9Ycp6F6bo55eaA2tAclWWM7U-UTaGlCJ2eoyzgHjQnOmjTD3L1P8y5R9YUmkc</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Eskiizmir, Görkem</creator><creator>Çalıbaşı, Gizem</creator><creator>Uysal, Tuğba</creator><creator>Ellidokuz, Hülya</creator><creator>Baskın, Yasemin</creator><general>Continuous Education and Scientific Research Association (CESRA)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20161201</creationdate><title>Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study</title><author>Eskiizmir, Görkem ; Çalıbaşı, Gizem ; Uysal, Tuğba ; Ellidokuz, Hülya ; Baskın, Yasemin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c192t-a5168c22d9b3cbc1586eaa421edbbefd7699e891ec02fd1a78209ceb7fdcd1953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Oral cancer</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eskiizmir, Görkem</creatorcontrib><creatorcontrib>Çalıbaşı, Gizem</creatorcontrib><creatorcontrib>Uysal, Tuğba</creatorcontrib><creatorcontrib>Ellidokuz, Hülya</creatorcontrib><creatorcontrib>Baskın, Yasemin</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>ENT updates</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eskiizmir, Görkem</au><au>Çalıbaşı, Gizem</au><au>Uysal, Tuğba</au><au>Ellidokuz, Hülya</au><au>Baskın, Yasemin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study</atitle><jtitle>ENT updates</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>6</volume><issue>3</issue><spage>105</spage><epage>109</epage><pages>105-109</pages><issn>2149-7109</issn><eissn>2149-6498</eissn><abstract>Objective: To evaluate the antitumor effect of cetuximab as a single agent for the treatment of oral cavity cancers and to clarify the dose-dependent growth inhibitory effect in oral cavity squamous cell carcinoma cell line (OCSCCCL). Methods: The OCSCCCL (UPCI-SCC131) were cultured and continuously monitored using the xCELLigence RTCA SP instrument. Thereafter, they were divided into seven groups as: (i) negative control: medium+OCSCCCL, (ii) positive control: medium+OCSCCCL+cisplatin 10 µM/ml, (iii) medium+OCSCCCL+cetuximab 25 µg/ml, (iv) medium+OCSCCCL+cetuximab 50 µg/ml, (v) medium+OCSCCCL+ cetuximab 100 µg/ml, (vi) medium+OCSCCCL+cetuximab 200 µg/ml, (vii) medium+OCSCCCL+cetuximab 400 µg/ml. The cell index and viability were statistically analyzed and compared between groups. Results: The distribution of cell index (mean value) and percentage of viability in groups were as follows: (i) 2.66 (100%), (ii) 0.17 (6.08%), (iii) 2.28 (85.71%), (iv) 2.31 (86.84%), (v) 1.92 (72.18%), (vi) 1.79 (67.29%), (vii) 0.28 (10.53%). The change trend in drug concentration was statistically different in all study groups to which cetuximab was administered (Pillai's trace; p&lt;0.0001). The antitumor effect of cetuximab was initially detected at a dose of 100 µg/mL, when compared with negative control (p=0.01). However, a dose of 400 µg/mL was required in order to have a statistically similar antitumor effect of cisplatin at a dose of 10 µM. Conclusion: Cetuximab alone is a potentially effective chemotherapeutic agent and has a concentration-dependent growth inhibitory effect in OCSCCCL. The antitumor activity of cetuximab was initially detected at a dose of 100 µg/mL. However, significant antitumor effect was determined at a dose of 400 µg/mL.</abstract><cop>Istanbul</cop><pub>Continuous Education and Scientific Research Association (CESRA)</pub><doi>10.2399/jmu.2016003005</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2149-7109
ispartof ENT updates, 2016-12, Vol.6 (3), p.105-109
issn 2149-7109
2149-6498
language eng
recordid cdi_crossref_primary_10_2399_jmu_2016003005
source EZB-FREE-00999 freely available EZB journals
subjects Immunotherapy
Monoclonal antibodies
Oral cancer
Targeted cancer therapy
title Cetuximab alone has a dose-dependent antitumor effect in oral cavity cancer cells: an in vitro study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A44%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cetuximab%20alone%20has%20a%20dose-dependent%20antitumor%20effect%20in%20oral%20cavity%20cancer%20cells:%20an%20in%20vitro%20study&rft.jtitle=ENT%20updates&rft.au=Eskiizmir,%20G%C3%B6rkem&rft.date=2016-12-01&rft.volume=6&rft.issue=3&rft.spage=105&rft.epage=109&rft.pages=105-109&rft.issn=2149-7109&rft.eissn=2149-6498&rft_id=info:doi/10.2399/jmu.2016003005&rft_dat=%3Cproquest_cross%3E1908931744%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1908931744&rft_id=info:pmid/&rfr_iscdi=true